Casgevy Commercialization

CRISPR Therapeutics has advanced the commercialization of its FDA‑approved gene‑editing therapy Casgevy for sickle cell disease and beta‑thalassemia, securing reimbursement and access agreements that cover the majority of eligible U.S. patients and outlining expansions into Europe and the Middle East. In its most recent quarter, the company reported revenue of $864 000 and a loss of $1.37 per share, exceeding analysts’ loss estimate of $1.20. Vertex Pharmaceuticals, the commercial partner for Casgevy, anticipates “$500 million or more in revenue from non‑CF products, including increased patient infusions of Casgevy through its global ATC network” in 2026. The quarterly net loss widened to $130.61 million, and annual losses reached $581.60 million on revenue of $3.51 million.